Finance Receivables was SWK Holdings’s largest segment in fiscal 2019, bringing in $60.23M of $62.52M (96%).
| Financing Receivable Portfolio Segment | FY 2019 |
|---|---|
| Finance Receivables | $60.23M |
| Pharmaceutical Development | $2.27M |
| Holding Company & Other | $18.00K |
| Total | $62.52M |
SWK Holdings brought in $62.52M from its three segments in fiscal 2019, the year ended December 31, 2019. Finance Receivables was the largest at $60.23M (96.3%), ahead of Pharmaceutical Development at $2.27M (3.6%) and Holding Company & Other at $18.00K (0.0%).
SWK Holdings (SWKHL) reports its revenue by financing receivable portfolio segment. In fiscal 2019, Finance Receivables was its largest segment, bringing in $60.23M (96.3% of the total), followed by Pharmaceutical Development at $2.27M (3.6%).
Finance Receivables was SWK Holdings' largest segment in fiscal 2019, bringing in $60.23M, or 96.3% of the $62.52M total across its three segments.
Every figure comes from SWK Holdings' annual financial filings, as reported. Each line keeps the name SWK Holdings gives it, and years follow its fiscal calendar.
SWK Holdings' revenue by financing receivable portfolio segment goes back to fiscal 2019, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.